Office of Management and Budget Click to print this document

Public Comment Regarding: FDA Policy on Use of Ozone-Depleting Substances in Medical Products

Date: 6/17/2002

Signer Organization
David D. Doniger - Senior Attorney and Policy Director - NRDC Climate Center
Return to this article at:
/omb/oira/0910/comments/371.html

Click to print this document